<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878238</url>
  </required_header>
  <id_info>
    <org_study_id>ACNE_PROB</org_study_id>
    <nct_id>NCT03878238</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Evaluate the Effect of a Probiotic Mixture in Acne</brief_title>
  <official_title>Randomized, Double Blind and Placebo-controlled Pilot Study to Evaluate the Effect of a Probiotic Mixture in Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionou Research, S.L.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionou Research, S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12-week randomized, double-blind, placebo-controlled pilot study to evaluate the effect of
      a probiotic blend in the treatment and clinical and subjective evolution of acne vulgaris in
      adolescent and adult patients between 12 and 30 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Actual">May 29, 2019</completion_date>
  <primary_completion_date type="Actual">April 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in GAGS (Global Acne Grading System) index score at 12 weeks</measure>
    <time_frame>12-week</time_frame>
    <description>TOTAL SCORE = Nose S x 1 + Chin S x 1 + Front S x 2 + Right cheek S x 2 + Left cheek S x 2 + Torso S x 3
[Severity (S): 0 = Absence; 1 = Comedones; 2 = Papules; 3 = Pustules; 4 = Nodules]
SCORE: 0 = Clean; 1-18 = Mild; 19-30 = Moderate; 31-38 = Severe; &gt; 38 = Very severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AGSS (Acne Global Severity Scale) index score</measure>
    <time_frame>0, 6 and 12-week</time_frame>
    <description>Score between 0 and 5:
0 = Clean = Normal and clear skin without evidence of acne
= Almost clean = There are some non-inflammatory lesions, with uncommon and non-inflamed papules
= Mild = few inflammatory lesions (no nodule-cystic lesions)
= Moderate = Noninflammatory lesions predominate, but multiple inflammatory lesions appear (nodule-cystic lesions may be present)
= Severe = Inflammatory lesions predominate (nodule-cystic lesions may be present)
= Very severe = Highly inflammatory lesions predominate (several nodule-cystic lesions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of acne lesions</measure>
    <time_frame>0, 6 and 12-week</time_frame>
    <description>Number of non-inflammatory, inflammatory and total acne lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation</measure>
    <time_frame>0, 6 and 12-week</time_frame>
    <description>Min score (Best) = 6 Max score (Worst) = 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>12-week</time_frame>
    <description>Compliance rate (in percentage) calculated as the number of leftover capsules divided by the total number of days between visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment safety assessed by number of adverse events</measure>
    <time_frame>12-week</time_frame>
    <description>Number of adverse events that occur during the treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Acne</condition>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic Bths-003</intervention_name>
    <description>Probiotic with maltodextrin as a carrier.</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with maltodextrin base.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signature of informed consent by the patient (and their legal guardian in case of
             being under age).

          -  Age between 12 and 30 years-old.

          -  Moderate acne according to the AGSS (Acne Global Severity Scale) and / or GAGS (Global
             Acne Grading System) scales.

        Exclusion Criteria:

          -  Contraindication of any of the components of the product under study.

          -  Topical or systemic use of antifungals and antibiotics in the previous 2 weeks.

          -  Consumption of probiotics in the previous 2 months.

          -  Use of systemic retinoids in the previous 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Vithas Nisa 9 de Octubre</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

